CN108853501B - 磁感蛋白在改善神经退行性疾病中的应用 - Google Patents
磁感蛋白在改善神经退行性疾病中的应用 Download PDFInfo
- Publication number
- CN108853501B CN108853501B CN201710317702.6A CN201710317702A CN108853501B CN 108853501 B CN108853501 B CN 108853501B CN 201710317702 A CN201710317702 A CN 201710317702A CN 108853501 B CN108853501 B CN 108853501B
- Authority
- CN
- China
- Prior art keywords
- protein
- magnetoinductive
- group
- magnetosensitive
- neurodegenerative diseases
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 108090000623 proteins and genes Proteins 0.000 title claims abstract description 97
- 102000004169 proteins and genes Human genes 0.000 title claims abstract description 77
- 208000015122 neurodegenerative disease Diseases 0.000 title abstract description 35
- 230000004770 neurodegeneration Effects 0.000 title abstract description 34
- 239000003814 drug Substances 0.000 claims abstract description 14
- 108010051975 Glycogen Synthase Kinase 3 beta Proteins 0.000 claims abstract description 13
- 102000003802 alpha-Synuclein Human genes 0.000 claims abstract description 13
- 108090000185 alpha-Synuclein Proteins 0.000 claims abstract description 13
- 239000013598 vector Substances 0.000 claims abstract description 8
- 208000024827 Alzheimer disease Diseases 0.000 claims description 26
- 208000018737 Parkinson disease Diseases 0.000 claims description 23
- 230000006907 apoptotic process Effects 0.000 claims description 17
- 241000665848 Isca Species 0.000 claims description 16
- 239000007924 injection Substances 0.000 claims description 15
- 238000002347 injection Methods 0.000 claims description 15
- 229940079593 drug Drugs 0.000 claims description 5
- 230000002401 inhibitory effect Effects 0.000 claims description 5
- 241000700605 Viruses Species 0.000 claims description 4
- 230000006872 improvement Effects 0.000 claims description 4
- 239000013603 viral vector Substances 0.000 claims description 3
- 102000019058 Glycogen Synthase Kinase 3 beta Human genes 0.000 claims 1
- 239000002552 dosage form Substances 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 claims 1
- 108700000707 bcl-2-Associated X Proteins 0.000 abstract description 13
- 102000055102 bcl-2-Associated X Human genes 0.000 abstract description 13
- 102100038104 Glycogen synthase kinase-3 beta Human genes 0.000 abstract description 12
- 238000002474 experimental method Methods 0.000 abstract description 12
- 230000002829 reductive effect Effects 0.000 abstract description 10
- 230000009471 action Effects 0.000 abstract description 9
- 230000004083 survival effect Effects 0.000 abstract description 9
- 102100021569 Apoptosis regulator Bcl-2 Human genes 0.000 abstract description 8
- 101000971171 Homo sapiens Apoptosis regulator Bcl-2 Proteins 0.000 abstract description 8
- 230000001976 improved effect Effects 0.000 abstract description 8
- 230000000694 effects Effects 0.000 abstract description 5
- 230000007087 memory ability Effects 0.000 abstract description 5
- 238000010353 genetic engineering Methods 0.000 abstract description 4
- 238000011552 rat model Methods 0.000 abstract description 3
- 210000001320 hippocampus Anatomy 0.000 abstract description 2
- 241000700159 Rattus Species 0.000 description 45
- 210000004027 cell Anatomy 0.000 description 26
- 210000002569 neuron Anatomy 0.000 description 15
- 230000006698 induction Effects 0.000 description 13
- 238000000034 method Methods 0.000 description 13
- 210000004556 brain Anatomy 0.000 description 11
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 10
- 238000011160 research Methods 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- 108010025020 Nerve Growth Factor Proteins 0.000 description 6
- 102000007072 Nerve Growth Factors Human genes 0.000 description 6
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 6
- 210000003140 lateral ventricle Anatomy 0.000 description 6
- 230000015654 memory Effects 0.000 description 6
- 239000003900 neurotrophic factor Substances 0.000 description 6
- 102000000584 Calmodulin Human genes 0.000 description 5
- 108010041952 Calmodulin Proteins 0.000 description 5
- 206010008025 Cerebellar ataxia Diseases 0.000 description 5
- 102000008186 Collagen Human genes 0.000 description 5
- 108010035532 Collagen Proteins 0.000 description 5
- FMGYKKMPNATWHP-UHFFFAOYSA-N Cyperquat Chemical compound C1=C[N+](C)=CC=C1C1=CC=CC=C1 FMGYKKMPNATWHP-UHFFFAOYSA-N 0.000 description 5
- 102000008857 Ferritin Human genes 0.000 description 5
- 108050000784 Ferritin Proteins 0.000 description 5
- 238000008416 Ferritin Methods 0.000 description 5
- 102000002812 Heat-Shock Proteins Human genes 0.000 description 5
- 108010004889 Heat-Shock Proteins Proteins 0.000 description 5
- 102000001554 Hemoglobins Human genes 0.000 description 5
- 108010054147 Hemoglobins Proteins 0.000 description 5
- 208000023105 Huntington disease Diseases 0.000 description 5
- 102000004877 Insulin Human genes 0.000 description 5
- 108090001061 Insulin Proteins 0.000 description 5
- 102000005298 Iron-Sulfur Proteins Human genes 0.000 description 5
- 108010081409 Iron-Sulfur Proteins Proteins 0.000 description 5
- 102000011782 Keratins Human genes 0.000 description 5
- 108010076876 Keratins Proteins 0.000 description 5
- 238000012347 Morris Water Maze Methods 0.000 description 5
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 5
- 229920001436 collagen Polymers 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 229940125396 insulin Drugs 0.000 description 5
- 208000002320 spinal muscular atrophy Diseases 0.000 description 5
- 230000009182 swimming Effects 0.000 description 5
- 102000014461 Ataxins Human genes 0.000 description 4
- 108010078286 Ataxins Proteins 0.000 description 4
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 4
- 108010026552 Proteome Proteins 0.000 description 4
- 102000013535 Proto-Oncogene Proteins c-bcl-2 Human genes 0.000 description 4
- 108010090931 Proto-Oncogene Proteins c-bcl-2 Proteins 0.000 description 4
- 206010039966 Senile dementia Diseases 0.000 description 4
- 208000009415 Spinocerebellar Ataxias Diseases 0.000 description 4
- 201000004562 autosomal dominant cerebellar ataxia Diseases 0.000 description 4
- 230000033228 biological regulation Effects 0.000 description 4
- 229910001424 calcium ion Inorganic materials 0.000 description 4
- 238000012258 culturing Methods 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 230000018109 developmental process Effects 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 4
- 230000003291 dopaminomimetic effect Effects 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- 230000008506 pathogenesis Effects 0.000 description 4
- 230000001105 regulatory effect Effects 0.000 description 4
- 210000003523 substantia nigra Anatomy 0.000 description 4
- 238000012549 training Methods 0.000 description 4
- 201000008163 Dentatorubral pallidoluysian atrophy Diseases 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 3
- 208000033063 Progressive myoclonic epilepsy Diseases 0.000 description 3
- 238000002835 absorbance Methods 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 229930195712 glutamate Natural products 0.000 description 3
- 229960003180 glutathione Drugs 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 230000001939 inductive effect Effects 0.000 description 3
- 108091005981 phosphorylated proteins Proteins 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 230000000750 progressive effect Effects 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- WQZGKKKJIJFFOK-SVZMEOIVSA-N (+)-Galactose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-SVZMEOIVSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 102000018899 Glutamate Receptors Human genes 0.000 description 2
- 108010027915 Glutamate Receptors Proteins 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 230000006909 anti-apoptosis Effects 0.000 description 2
- 108700041737 bcl-2 Genes Proteins 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 210000005013 brain tissue Anatomy 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 230000005779 cell damage Effects 0.000 description 2
- 208000037887 cell injury Diseases 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 230000019771 cognition Effects 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 229960003638 dopamine Drugs 0.000 description 2
- 210000005064 dopaminergic neuron Anatomy 0.000 description 2
- 230000002996 emotional effect Effects 0.000 description 2
- -1 etc.) Substances 0.000 description 2
- 230000003492 excitotoxic effect Effects 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 230000000971 hippocampal effect Effects 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 239000007928 intraperitoneal injection Substances 0.000 description 2
- 239000006166 lysate Substances 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 210000003061 neural cell Anatomy 0.000 description 2
- 230000004112 neuroprotection Effects 0.000 description 2
- 230000036542 oxidative stress Effects 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000004224 protection Effects 0.000 description 2
- 239000013646 rAAV2 vector Substances 0.000 description 2
- 239000003642 reactive oxygen metabolite Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 102000013498 tau Proteins Human genes 0.000 description 2
- 108010026424 tau Proteins Proteins 0.000 description 2
- BRAJQLYTRXKQAW-UHFFFAOYSA-N 1-methyl-4-phenyl-2h-pyridine Chemical compound C1=CN(C)CC=C1C1=CC=CC=C1 BRAJQLYTRXKQAW-UHFFFAOYSA-N 0.000 description 1
- 208000000044 Amnesia Diseases 0.000 description 1
- 208000031091 Amnestic disease Diseases 0.000 description 1
- 102000013455 Amyloid beta-Peptides Human genes 0.000 description 1
- 108010090849 Amyloid beta-Peptides Proteins 0.000 description 1
- 102000014303 Amyloid beta-Protein Precursor Human genes 0.000 description 1
- 108010079054 Amyloid beta-Protein Precursor Proteins 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 102000051485 Bcl-2 family Human genes 0.000 description 1
- 108700038897 Bcl-2 family Proteins 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241001573498 Compacta Species 0.000 description 1
- IVOMOUWHDPKRLL-KQYNXXCUSA-N Cyclic adenosine monophosphate Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-KQYNXXCUSA-N 0.000 description 1
- 206010012289 Dementia Diseases 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- VTLYFUHAOXGGBS-UHFFFAOYSA-N Fe3+ Chemical compound [Fe+3] VTLYFUHAOXGGBS-UHFFFAOYSA-N 0.000 description 1
- 229940123457 Free radical scavenger Drugs 0.000 description 1
- 108091006151 Glutamate transporters Proteins 0.000 description 1
- 102000034575 Glutamate transporters Human genes 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 101710088172 HTH-type transcriptional regulator RipA Proteins 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 238000000134 MTT assay Methods 0.000 description 1
- 231100000002 MTT assay Toxicity 0.000 description 1
- 108020005196 Mitochondrial DNA Proteins 0.000 description 1
- 229940099433 NMDA receptor antagonist Drugs 0.000 description 1
- 206010028851 Necrosis Diseases 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 208000025966 Neurological disease Diseases 0.000 description 1
- 108010019160 Pancreatin Proteins 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 102000003982 Parathyroid hormone Human genes 0.000 description 1
- 108090000445 Parathyroid hormone Proteins 0.000 description 1
- 208000027089 Parkinsonian disease Diseases 0.000 description 1
- 206010034010 Parkinsonism Diseases 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 229940122907 Phosphatase inhibitor Drugs 0.000 description 1
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 1
- 108700025695 Suppressor Genes Proteins 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 102000030621 adenylate cyclase Human genes 0.000 description 1
- 108060000200 adenylate cyclase Proteins 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 230000006986 amnesia Effects 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 230000002424 anti-apoptotic effect Effects 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 229940124599 anti-inflammatory drug Drugs 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000006851 antioxidant defense Effects 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 101150024147 bax gene Proteins 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000004958 brain cell Anatomy 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 230000009460 calcium influx Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000006727 cell loss Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 230000006567 cellular energy metabolism Effects 0.000 description 1
- RNFNDJAIBTYOQL-UHFFFAOYSA-N chloral hydrate Chemical compound OC(O)C(Cl)(Cl)Cl RNFNDJAIBTYOQL-UHFFFAOYSA-N 0.000 description 1
- 229960002327 chloral hydrate Drugs 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 208000010877 cognitive disease Diseases 0.000 description 1
- 230000003920 cognitive function Effects 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000000875 corresponding effect Effects 0.000 description 1
- 238000005138 cryopreservation Methods 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 210000001951 dura mater Anatomy 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 231100000318 excitotoxic Toxicity 0.000 description 1
- 239000004060 excitotoxin Substances 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 229910001447 ferric ion Inorganic materials 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000005891 glutamate uptake involved in synaptic transmission Effects 0.000 description 1
- 230000000848 glutamatergic effect Effects 0.000 description 1
- 210000001362 glutamatergic neuron Anatomy 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 210000001879 hippocampal ca1 region Anatomy 0.000 description 1
- 238000010191 image analysis Methods 0.000 description 1
- 238000011532 immunohistochemical staining Methods 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- XEEYBQQBJWHFJM-UHFFFAOYSA-N iron Substances [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 210000000274 microglia Anatomy 0.000 description 1
- 230000006724 microglial activation Effects 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 230000004065 mitochondrial dysfunction Effects 0.000 description 1
- 230000004898 mitochondrial function Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000007659 motor function Effects 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 239000003703 n methyl dextro aspartic acid receptor blocking agent Substances 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 210000001178 neural stem cell Anatomy 0.000 description 1
- 210000004498 neuroglial cell Anatomy 0.000 description 1
- 239000004090 neuroprotective agent Substances 0.000 description 1
- 230000002887 neurotoxic effect Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 210000004248 oligodendroglia Anatomy 0.000 description 1
- 230000010627 oxidative phosphorylation Effects 0.000 description 1
- 229940055695 pancreatin Drugs 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 239000000199 parathyroid hormone Substances 0.000 description 1
- 229960001319 parathyroid hormone Drugs 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000009323 psychological health Effects 0.000 description 1
- 239000002516 radical scavenger Substances 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 238000010814 radioimmunoprecipitation assay Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 210000004761 scalp Anatomy 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000012764 semi-quantitative analysis Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 210000003625 skull Anatomy 0.000 description 1
- 229940126586 small molecule drug Drugs 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 238000011476 stem cell transplantation Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 210000004281 subthalamic nucleus Anatomy 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
- A61K9/0009—Galenical forms characterised by the drug release technique; Application systems commanded by energy involving or responsive to electricity, magnetism or acoustic waves; Galenical aspects of sonophoresis, iontophoresis, electroporation or electroosmosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Dermatology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
组别 | OD值 | 存活率/% |
对照组 | 0.852±0.012 | 100 |
模型组 | 0.498±0.013 | 58.5 |
磁感蛋白组 | 0.604±0.033 | 70.9 |
磁场组 | 0.764±0.014 | 89.7 |
组别 | 平均逃避潜伏期(s) | 穿越平台次数 |
对照组 | 14.86±3.12 | 7.95±0.86 |
模型组 | 57.25±6.13 | 2.86±0.72 |
磁感蛋白组 | 46.25±3.33 | 3.83±0.52 |
磁场组 | 24.76±4.18 | 6.86±0.96 |
组别 | Bcl-2蛋白 | Bax蛋白 |
对照组 | 0.15±0.02 | 0.26±0.02 |
模型组 | 0.37±0.05 | 0.75±0.03 |
磁感蛋白组 | 0.42±0.03 | 0.64±0.05 |
磁场组 | 0.47±0.04 | 0.39±0.04 |
Claims (5)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201710317702.6A CN108853501B (zh) | 2017-05-08 | 2017-05-08 | 磁感蛋白在改善神经退行性疾病中的应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201710317702.6A CN108853501B (zh) | 2017-05-08 | 2017-05-08 | 磁感蛋白在改善神经退行性疾病中的应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN108853501A CN108853501A (zh) | 2018-11-23 |
CN108853501B true CN108853501B (zh) | 2021-02-02 |
Family
ID=64287270
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201710317702.6A Active CN108853501B (zh) | 2017-05-08 | 2017-05-08 | 磁感蛋白在改善神经退行性疾病中的应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN108853501B (zh) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110045300B (zh) * | 2019-04-08 | 2020-06-02 | 东南大学 | 基于磁感应蛋白探测磁场的传感器 |
CN114209717A (zh) * | 2021-12-29 | 2022-03-22 | 贵州广济堂健康药业有限公司 | 鹿胶及其药物组合物和用途 |
CN114908055B (zh) * | 2022-05-13 | 2024-03-12 | 东南大学 | 过表达Magr调节体内铁稳态的干细胞及制备方法 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004041169A2 (en) * | 2002-10-30 | 2004-05-21 | Bach Pharma, Inc | Modulation of cell fates and activities by phthalazine diones |
WO2014090313A1 (en) * | 2012-12-13 | 2014-06-19 | Universitaet Ulm | Nanoparticle with a molecularly imprinted coating |
CN106146650A (zh) * | 2015-04-10 | 2016-11-23 | 北京大学 | 磁感应受体蛋白和其复合物及它们的用途 |
-
2017
- 2017-05-08 CN CN201710317702.6A patent/CN108853501B/zh active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004041169A2 (en) * | 2002-10-30 | 2004-05-21 | Bach Pharma, Inc | Modulation of cell fates and activities by phthalazine diones |
WO2014090313A1 (en) * | 2012-12-13 | 2014-06-19 | Universitaet Ulm | Nanoparticle with a molecularly imprinted coating |
CN106146650A (zh) * | 2015-04-10 | 2016-11-23 | 北京大学 | 磁感应受体蛋白和其复合物及它们的用途 |
Non-Patent Citations (3)
Title |
---|
ISCA2 mutation causes infantile neurodegenerative mitochondrial disorder;Al-Hassnan ZN等;《Journal of medical genetics》;20141224;第52卷(第3期);第186-194页 * |
Magnetogenetics: remote non-invasive magnetic activation of neuronal activity with a magnetoreceptor;Xiaoyang Long等;《Science Bulletin》;20150914;第60卷(第24期);第2107-2119页 * |
生物磁受体蛋白MagR/IscA研究进展;汪红霞等;《生物化学与生物物理进展》;20161231;第43卷(第12期);第1115-1128页 * |
Also Published As
Publication number | Publication date |
---|---|
CN108853501A (zh) | 2018-11-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Gaojian et al. | Parthenolide promotes the repair of spinal cord injury by modulating M1/M2 polarization via the NF-κB and STAT 1/3 signaling pathway | |
Tajiri et al. | Exercise exerts neuroprotective effects on Parkinson's disease model of rats | |
Lee et al. | Effects of systemic administration of ibuprofen on stress response in a rat model of post-traumatic stress disorder | |
CN108853501B (zh) | 磁感蛋白在改善神经退行性疾病中的应用 | |
Li et al. | Recovery of post-stroke cognitive and motor deficiencies by Shuxuening injection via regulating hippocampal BDNF-mediated Neurotrophin/Trk Signaling | |
US6165515A (en) | Method for treatment of osteoporosis | |
Ifeanyi | A review on erythropoietin | |
Ma et al. | The effect of acori graminei rhizoma and extract fractions on spatial memory and hippocampal neurogenesis in amyloid beta 1-42 injected mice | |
RU2416426C2 (ru) | Новое применение | |
Fadeev et al. | Combination of epidural electrical stimulation with ex vivo triple gene therapy for spinal cord injury: a proof of principle study | |
Li et al. | Coeloglossum viride var. bracteatum extract attenuates Aβ-induced toxicity by inhibiting RIP1–driven inflammation and necroptosis | |
Barker et al. | Neural repair, transplantation, and rehabilitation | |
Zhang et al. | Anti-inflammatory effects of aucubin in cellular and animal models of rheumatoid arthritis | |
KR102563524B1 (ko) | 미토콘드리아를 포함하는 골관절염의 예방 또는 치료용 조성물 | |
Ma et al. | Tofacitinib promotes functional recovery after spinal cord injury by regulating microglial polarization via JAK/STAT signaling pathway | |
Arezoomandan et al. | Administration of the glial condition medium in the nucleus accumbens prolong maintenance and intensify reinstatement of morphine-seeking behavior | |
CN110151833A (zh) | 一种治疗阿尔兹海默症的药物组合物 | |
Li et al. | Buyang Huanwu Decoction promotes the neurological recovery of traumatic spinal cord injury via inhibiting apoptosis, inflammation, and oxidative stress | |
KR20150059671A (ko) | 인간 골수 유래 중간엽 줄기세포를 유효성분으로 포함하는 파킨슨 증후군의 예방 또는 치료용 약제학적 조성물 | |
CN113181216B (zh) | 一种间充质干细胞外泌体-am1241复合体及其在治疗阿尔茨海默病中的应用 | |
CN108096243A (zh) | 银杏内酯组合物的医药用途 | |
EP2883569B1 (en) | Compositions comprising plasma growth factors for use in the treatment of neurodegenerative disorders | |
WO2022113667A1 (ja) | ミクログリア含有中枢神経系内移動剤、及びこれを含む中枢神経系疾患治療薬、並びにミクログリア導入動物、及びその製造方法 | |
Quan et al. | The mechanism of chemokine receptor ACKR2 in cognitive impairment in young rats with traumatic brain injury | |
CN108186616A (zh) | β-榄香烯在制备用于预防和/或治疗与IL-1相关的炎症性疾病的药物中的用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
CP01 | Change in the name or title of a patent holder | ||
CP01 | Change in the name or title of a patent holder |
Address after: 313300, Zhejiang County, Huzhou province Anji County pass Town Health Industry Park Patentee after: Heye Health Technology Co.,Ltd. Address before: 313300, Zhejiang County, Huzhou province Anji County pass Town Health Industry Park Patentee before: Zhejiang Heye Health Technology Co.,Ltd. |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Application of magnetic sensing protein in improving neurodegenerative diseases Effective date of registration: 20210819 Granted publication date: 20210202 Pledgee: Zhejiang Anji Rural Commercial Bank of the West Branch of Limited by Share Ltd. Pledgor: Heye Health Technology Co.,Ltd. Registration number: Y2021330001178 |
|
PC01 | Cancellation of the registration of the contract for pledge of patent right | ||
PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20221020 Granted publication date: 20210202 Pledgee: Zhejiang Anji Rural Commercial Bank of the West Branch of Limited by Share Ltd. Pledgor: Heye Health Technology Co.,Ltd. Registration number: Y2021330001178 |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Application of magnetic induction protein in improving neurodegenerative diseases Effective date of registration: 20221127 Granted publication date: 20210202 Pledgee: Zhejiang Anji Rural Commercial Bank of the West Branch of Limited by Share Ltd. Pledgor: Heye Health Technology Co.,Ltd. Registration number: Y2022330003259 |
|
PC01 | Cancellation of the registration of the contract for pledge of patent right | ||
PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20231009 Granted publication date: 20210202 Pledgee: Zhejiang Anji Rural Commercial Bank of the West Branch of Limited by Share Ltd. Pledgor: Heye Health Technology Co.,Ltd. Registration number: Y2022330003259 |